XM does not provide services to residents of the United States of America.
P
P

Pfizer

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Vista and Blackstone in talks to acquire software maker Smartsheet, sources say

EXCLUSIVE-Vista and Blackstone in talks to acquire software maker Smartsheet, sources say Adds more details and background on Smartsheet By Milana Vinn NEW YORK, Sept 5 (Reuters) - A private equity consortium including Vista Equity Partners and Blackstone BX.N is in talks to acquire Smartsheet SMAR.N , a U.S. maker of workplace collaboration software with a market value of about $7 billion, people familiar with the matter said on Thursday.
C
P

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high Sept 5 (Reuters) - Vaxcyte PCVX.O , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high on promising results in a vaccine trial.
G
P

Alert incorrectly tagged to Trane Technologies withdrawn

ADVISORY-Alert incorrectly tagged to Trane Technologies withdrawn An alert on Acepodia 6976.TWO entering a strategic clinical collaboration with Pfizer PFE.N was incorrectly tagged to Trane Technologies 2IS.F , an unrelated entity, and has been withdrawn. For the correctly coded alerts, click nFWN3KL1PM STORY_NUMBER:nTUA2X1ZQB STORY_DATE:03/09/2024
P

What to Watch in the Day Ahead - Wednesday, September 4

What to Watch in the Day Ahead - Wednesday, September 4 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT U.S. investors will look forward to the Labor Department's Job Openings and Labor Turnover Survey, or JOLTS report.
B
G
P
D

Vaxcyte's shares hit record high after early data on pneumococcal vaccine

UPDATE 2-Vaxcyte's shares hit record high after early data on pneumococcal vaccine Updates shares in paragraphs 5 and 10, details on public offering in paragraph 6 Sept 3 (Reuters) - Vaxcyte's PCVX.O shares surged as much as 48% to a record high on Tuesday after the company said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety profile similar to rival Pfizer's PFE.N shot.
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.